Although association between angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism and cardiovascular diseases was reported by many studies, the relation between ACE I/D polymorphism and coronary collateral circulation (CCC) has not been studied yet. The aim of the present study was to investigate a possible relationship between ACE I/D polymorphism and CCC.
Methods
Patients who were subjected to coronary angiography in the 2006 to 2009 period and had at least a completely occluded major artery were included in this study. To classify collateral circulation, we used the Rentrop classification. Patients were classified as having poor CCC (Rentrop grades 0 to 1) or good CCC (Rentrop grades 2 to 3). Gene polymorphism was detected through the detailed melting curve analysis of polymerase chain reaction products after amplification using real-time polymerase chain reaction method and LightCycler 1.5 apparatus.
Results
We prospectively studied 113 patients who had at least 1 totally occluded major epicardial coronary artery. Forty-seven patients had poor CCC and 67 patients had good CCC. There were no differences among groups in age, sex, risk factors, lipid profile, uses of cardiovascular drugs, and number of diseased vessels. Plasma ACE levels were significantly higher in poor CCC group (P < 0.001). The frequency of DD polymorphism was higher in the poor CCC group (P < 0.001). In allele frequency, we found that the frequency of the D allele was higher in poor CCC group than in the good CCC group (95% confidence interval [CI], 2.16–7.38; P < 0.001). Multiple regression analysis with CCC development as the dependent variable revealed that the presence of total occlusion of the left circumflex artery (95% CI, 1.29–6.6; P = 0.001), ACE DD genotype (95% CI, 2.55–12.79; P = 0.001), presence of diabetes (95% CI, 1.03–3.16; P = 0.005), and pulse pressure (95% CI, 1.04–1.56; P = 0.045) were independent determinants of poor coronary collateral development.
Conclusions
This study showed that ACE DD polymorphism is associated with poor CCC. Poor collateral circulation in patients carrying the D allele may be associated with endothelial dysfunction and elevated blood ACE levels in these patients.
BaroldiG, ManteroO, ScomazzoniG.The collaterals of the coronary arteries in normal and pathologic hearts. Circ Res. 1956; 4: 223–229.
2.
UnthankJL, NixonJC, LashJM.Early adaptations in collateral and microvascular resistances after ligation of the rat femoral artery. J Appl Physiol. 1995; 79: 73–82.
3.
YangHT, RenJ, LaughlinMH, . Prior exercise training produces NO-dependent increases in collateral blood flow after acute arterial occlusion. Am J Physiol Heart Circ Physiol. 2002; 282: H301–H310.
4.
HelfantRH, VokonasPS, GorlinR.Functional importance of the human coronary collateral circulation. N Engl J Med. 1971; 284: 1277–1281.
5.
HabibGB, HeibigJ, FormanSA, . Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators. Circulation. 1991; 83: 739–746.
6.
YunJ, RocicP, PungYF, . Redox-dependent mechanisms in coronary collateral growth: the “redox window” hypothesis. Antioxid Redox Signal. 2009; 11: 1961–1974.
7.
HoeferIE, van RoyenN, RectenwaldJE, . Arteriogenesis proceeds via ICAM-1/Mac-1–mediated mechanisms. Circ Res. 2004; 94: 1179–1185.
8.
VoskuilM, van RoyenN, HoeferIE, . Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1. Am J Physiol Heart Circ Physiol. 2003; 284: H1422–H1428.
9.
HoeferIE, van RoyenN, RectenwaldJE, . Direct evidence for tumor necrosis factor-alpha signaling in arteriogenesis. Circulation. 2002; 105: 1639–1641.
10.
CarraoAC, ChilianWM, YunJ, . Stimulation of coronary collateral growth by granulocyte stimulating factor: role of reactive oxygen species. Arterioscler Thromb Vasc Biol. 2009; 29: 1817–1822.
11.
ChappellDC, VarnerSE, NeremRM, . Oscillatory shear stress stimulates adhesion molecule expression in cultured human endothelium. Circ Res. 1998; 82: 532–539.
12.
RocicP, KolzC, ReedR, . Optimal reactive oxygen species concentration and p38 MAP kinase are required for coronary collateral growth. Am J Physiol Heart Circ Physiol. 2007; 292: H2729–H2736.
13.
ToyotaE, WarltierDC, BrockT, . Vascular endothelial growth factor is required for coronary collateral growth in the rat. Circulation. 2005; 112: 2108–2113.
14.
MolnarGA, WagnerZ, WagnerL, . Effect of ACE gene polymorphism on carbohydrate metabolism, on oxidative stress and on end-organ damage in type-2 diabetes mellitus [in Hungarian]. Orv Hetil. 2004; 145: 855–859.
15.
GuzmanRJ, AbeK, ZarinsCK.Flow-induced arterial enlargement is inhibited by suppression of nitric oxide synthase activity in vivo. Surgery. 1997; 122: 273–279; discussion 279–280.
GulecS, KarabulutH, OzdemirAO, . Glu298Asp polymorphism of the eNOS gene is associated with coronary collateral development. Atherosclerosis. 2008; 198: 354–359.
20.
PohlT, SeilerC, BillingerM, . Frequency distribution of collateral flow and factors influencing collateral channel development. Functional collateral channel measurement in 450 patients with coronary artery disease. J Am Coll Cardiol. 2001; 38: 1872–1878.
21.
PiekJJ, van LiebergenRA, KochKT, . Clinical, angiographic and hemodynamic predictors of recruitable collateral flow assessed during balloon angioplasty coronary occlusion. J Am Coll Cardiol. 1997; 29: 275–282.
22.
FujitaM, NakaeI, KiharaY, . Determinants of collateral development in patients with acute myocardial infarction. Clin Cardiol. 1999; 22: 595–599.
23.
MelidonisA, TournisS, KouvarasG, . Comparison of coronary collateral circulation in diabetic and nondiabetic patients suffering from coronary artery disease. Clin Cardiol. 1999; 22: 465–471.
24.
Van BelleE, RivardA, ChenD, . Hypercholesterolemia attenuates angiogenesis but does not preclude augmentation by angiogenic cytokines. Circulation. 1997; 96: 2667–2674.
25.
RigatB, HubertC, Alhenc-GelasF, . An insertion/deletion polymorphism in the angiotensin I–converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86: 1343–1346.
26.
JalilJE, PalomeraC, OcaranzaMP, . Levels of plasma angiotensin-(1–7) in patients with hypertension who have the angiotensin-I–converting enzyme deletion/deletion genotype. Am J Cardiol. 2003; 92: 749–751.
27.
YangYH, LaiCL, TyanYC, . Angiotensin-converting enzyme gene and plasma protein level in Alzheimer's disease in Taiwanese. Age Ageing. 40: 238–242.
28.
Sayed-TabatabaeiFA, Houwing-DuistermaatJJ, van DuijnCM, . Angiotensin-converting enzyme gene polymorphism and carotid artery wall thickness: a meta-analysis. Stroke. 2003; 34: 1634–1639.
29.
PfohlM, AthanasiadisA, KochM, . Insertion/deletion polymorphism of the angiotensin I–converting enzyme gene is associated with coronary artery plaque calcification as assessed by intravascular ultrasound. J Am Coll Cardiol. 1998; 31: 987–991.
30.
OeiHH, Sayed-TabatabaeiFA, HofmanA, . The association between angiotensin-converting enzyme gene polymorphism and coronary calcification. The Rotterdam Coronary Calcification Study. Atherosclerosis. 2005; 182: 169–173.
31.
Agerholm-LarsenB, NordestgaardBG, Tybjaerg-HansenA.ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites. Arterioscler Thromb Vasc Biol. 2000; 20: 484–492.
32.
KeavneyB, McKenzieC, ParishS, . Large-scale test of hypothesised associations between the angiotensin-converting-enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet. 2000; 355: 434–442.
33.
SahnDJ, DeMariaA, KissloJ, . Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978; 58: 1072–1083.
34.
RentropKP, CohenM, BlankeH, . Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol. 1985; 5: 587–592.
35.
FultonD, GrattonJP, McCabeTJ, . Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999; 399: 597–601.
36.
MillerSJ, NortonLE, MurphyMP, . The role of the renin-angiotensin system and oxidative stress in spontaneously hypertensive rat mesenteric collateral growth impairment. Am J Physiol Heart Circ Physiol. 2007; 292: H2523–H2531.
37.
MatsunagaT, WarltierDC, WeihrauchDW, . Ischemia-induced coronary collateral growth is dependent on vascular endothelial growth factor and nitric oxide. Circulation. 2000; 102: 3098–3103.
38.
LuX, WuT, HuangP, . Effect and mechanism of intermittent myocardial ischemia induced by exercise on coronary collateral formation. Am J Phys Med Rehabil. 2008; 87: 803–814.
39.
MetaisC, LiJ, SimonsM, . Effects of coronary artery disease on expression and microvascular response to VEGF. Am J Physiol. 1998; 275: H1411–H1418.
40.
van der ZeeR, MuroharaT, LuoZ, . Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation. 1997; 95: 1030–1037.
41.
SellkeFW, WangSY, StamlerA, . Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. Am J Physiol. 1996; 271: H713–H720.
42.
YilmazMB, BiyikogluSF, AkinY, . Obesity is associated with impaired coronary collateral vessel development. Int J Obes Relat Metab Disord. 2003; 27: 1541–1545.
43.
TurhanH, YasarAS, ErbayAR, . Impaired coronary collateral vessel development in patients with metabolic syndrome. Coron Artery Dis. 2005; 16: 281–285.
44.
MouquetF, CuilleretF, SusenS, . Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1. Eur Heart J. 2009; 30: 840–849.
45.
PenesovaA, CizmarovaE, KvetnanskyR, . Insertion/deletion polymorphism on ACE gene is associated with endothelial dysfunction in young patients with hypertension. Horm Metab Res. 2006; 38: 592–597.
46.
YalcinAA, KalayN, CaglayanAO, . The relationship between slow coronary flow and angiotensin converting enzyme and ATIIR1 gene polymorphisms. J Natl Med Assoc. 2009; 101: 40–45.
47.
BuikemaH, PintoYM, RooksG, . The deletion polymorphism of the angiotensin-converting enzyme gene is related to phenotypic differences in human arteries. Eur Heart J. 1996; 17: 787–794.
48.
PerticoneF, CeravoloR, MaioR, . Angiotensin-converting enzyme gene polymorphism is associated with endothelium-dependent vasodilation in never treated hypertensive patients. Hypertension. 1998; 31: 900–905.
49.
ArcaroG, SoliniA, MonauniT, . ACE genotype and endothelium-dependent vasodilation of conduit arteries and forearm microcirculation in humans. Arterioscler Thromb Vasc Biol. 2001; 21: 1313–1319.
50.
SchunkertH, DzauVJ, TangSS, . Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. J Clin Invest. 1990; 86: 1913–1920.
51.
DanserAH, KoningMM, AdmiraalPJ, . Production of angiotensins I and II at tissue sites in intact pigs. Am J Physiol. 1992; 263: H429–H437.
52.
RajagopalanS, KurzS, MunzelT, . Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996; 97: 1916–1923.
53.
TouyzRM.Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance?Hypertension. 2004; 44: 248–252.
54.
CambienF, CosterousseO, TiretL, . Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation. 1994; 90: 669–676.
55.
TiretL, RigatB, VisvikisS, . Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I–converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992; 51: 197–205.
56.
GardemannA, WeissT, SchwartzO, . Gene polymorphism but not catalytic activity of angiotensin I–converting enzyme is associated with coronary artery disease and myocardial infarction in low-risk patients. Circulation. 1995; 92: 2796–2799.
57.
JalilJE, OcaranzaMP, PiddoAM, . Reproducibility of plasma angiotensin-converting enzyme activity in human subjects determined by fluorimetry with Z-phenylalanine-histidyl-leucine as substrate. J Lab Clin Med. 1999; 133: 501–506.
58.
VillardE, TiretL, VisvikisS, . Identification of new polymorphisms of the angiotensin I–converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis. Am J Hum Genet. 1996; 58: 1268–1278.
59.
TsutayaS, KitayaH, SaitoY, . Angiotensin converting enzyme gene polymorphism and its enzyme activity in serum in young Japanese females. Tohoku J Exp Med. 1997; 182: 151–155.
60.
NakaiK, ItohC, MiuraY, . Deletion polymorphism of the angiotensin I–converting enzyme gene associates with increased risk for ischemic heart diseases in the Japanese [in Japanese]. Rinsho Byori. 1994; 42: 689–694.
61.
ManciniGB, HenryGC, MacayaC, . Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 1996; 94: 258–265.
62.
MiuraS, NishikawaH, ZhangB, . Angiotensin-converting enzyme inhibitor promotes coronary collateral circulation in patients with coronary artery disease. Circ J. 2003; 67: 535–538.
63.
WarrenJB, LoiRK.Captopril increases skin microvascular blood flow secondary to bradykinin, nitric oxide, and prostaglandins. FASEB J. 1995; 9: 411–418.
64.
ReedR, KolzC, PotterB, . The mechanistic basis for the disparate effects of angiotensin II on coronary collateral growth. Arterioscler Thromb Vasc Biol. 2008; 28: 61–67.
65.
ImaizumiS, MiuraS, NishikawaH, . Angiotensin II type 1 receptor blockers do not promote coronary collateral circulation in patients with coronary artery disease. Hypertens Res. 2006; 29: 135–141.
66.
HillmeisterP, GatzkeN, DulsnerA, . Arteriogenesis is modulated on bradykinin receptor signaling. Circ Res. 2011; 109 (5): 524–533.
67.
MurpheyLJ, GainerJV, VaughanDE, . Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation. 2000; 102: 829–832.
68.
OzturkO, OzturkU.Relation between angiotensin-converting enzyme I/D gene polymorphism and pulse pressure in patients with a first anterior acute myocardial infarction. Anadolu Kardiyol Derg. 2009; 9: 9–14.
69.
IliaR, CarmelS, CafriC, . Coronary collaterals in patients with normal and impaired left ventricular systolic function. Int J Cardiol. 1998; 63: 151–153.
70.
AltinT, KilickapM, TutarE, . The relationship of chronic angiotensin converting enzyme inhibitor use and coronary collateral vessel development. Int Heart J. 2007; 48: 435–442.
71.
AbaciA, OguzhanA, KahramanS, . Effect of diabetes mellitus on formation of coronary collateral vessels. Circulation. 1999; 99: 2239–2242.
